LENSAR’s (LNSR) “Hold” Rating Reaffirmed at Lake Street Capital

Lake Street Capital reissued their hold rating on shares of LENSAR (NASDAQ:LNSR) in a report issued on Monday morning,Benzinga reports. Lake Street Capital currently has a $15.00 target price on the stock, down from their previous target price of $16.00.

LENSAR Price Performance

LNSR stock opened at $14.24 on Monday. The stock has a market capitalization of $167.88 million, a P/E ratio of -9.75 and a beta of 0.62. LENSAR has a fifty-two week low of $2.67 and a fifty-two week high of $17.31. The business has a 50-day moving average of $11.56 and a 200-day moving average of $8.25.

LENSAR (NASDAQ:LNSR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($1.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.40). LENSAR had a negative return on equity of 49.02% and a negative net margin of 34.03%. The firm had revenue of $16.73 million for the quarter, compared to analyst estimates of $14.95 million.

Institutional Investors Weigh In On LENSAR

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its position in shares of LENSAR by 3.5% in the third quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock valued at $460,000 after acquiring an additional 3,423 shares during the last quarter. Evernest Financial Advisors LLC bought a new position in LENSAR in the fourth quarter valued at approximately $174,000. Bailard Inc. acquired a new position in shares of LENSAR during the 4th quarter worth approximately $181,000. Atria Investments Inc increased its position in shares of LENSAR by 28.2% during the 4th quarter. Atria Investments Inc now owns 26,055 shares of the company’s stock worth $233,000 after purchasing an additional 5,729 shares during the last quarter. Finally, Essex Investment Management Co. LLC raised its stake in shares of LENSAR by 18.3% during the 4th quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company’s stock worth $357,000 after purchasing an additional 6,184 shares in the last quarter. 40.15% of the stock is owned by institutional investors.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.